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Antiretroviral therapy (ART) is unable to eradicate 
human immunodeficiency virus type 1 (HIV-1) infec-
tion. Therefore, there is an urgent need to develop 
novel therapies for this disease to augment anti-HIV 
immunity. T cell therapy is appealing in this regard as 
T cells have the ability to proliferate, migrate, and their 
antigen specificity reduces the possibility of off-target 
effects. However, past human studies in HIV-1 infection 
that administered T cells with limited specificity failed 
to provide ART-independent, long-term viral control. 
In this study, we sought to expand functional, broadly-
specific cytotoxic T cells (HXTCs) from HIV-infected 
patients on suppressive ART as a first step toward 
developing cellular therapies for implementation in 
future HIV eradication protocols. Blood samples from 
seven HIV+ patients on suppressive ART were used to 
derive HXTCs. Multiantigen specificity was achieved by 
coculturing T cells with antigen-presenting cells pulsed 
with peptides representing Gag, Pol, and Nef. All but 
two lines were multispecific for all three antigens. 
HXTCs demonstrated efficacy as shown by release of 
proinflammatory cytokines, specific lysis of antigen-
pulsed targets, and the ability to suppress HIV replica-
tion in vitro. In conclusion, we are able to generate 
broadly-specific cytotoxic T cell lines that simultane-
ously target multiple HIV antigens and show robust 
antiviral  function.
Received 30 June 2014; accepted 17 October 2014; advance online  
publication 25 November 2014. doi:10.1038/mt.2014.207
INTRODUCTION
Antiretroviral therapy (ART) prolongs the life of human immuno-
deficiency virus (HIV)–infected individuals by preventing progres-
sion to severe immunodeficiency, but ART cannot cure infection, 
and lifelong therapy is necessary to provide continuous viral sup-
pression. Populations that are at high risk for treatment nonadher-
ence are vulnerable to drug resistance and further transmission 
of HIV. Furthermore, the long-term use of ART may lead to side 
effects to the renal, hepatic, and cardiovascular systems.1
Recent efforts to develop therapies to eradicate HIV infection 
seek to avoid the lifelong dependency on ART by inducing the 
expression of persistent latent proviral genomes under the cover 
of continued ART, with the assistance of an augmented antiviral 
immune response.2 T cell therapy using cytotoxic T lymphocytes 
(CTLs) have proven successful in the treatment of virus-associ-
ated cancers and viral reactivation posttransplant.3–7 This type of 
therapy consists of expanding preexisting antigen-specific T cells 
from patients ex vivo until a sufficient number of cells are obtained 
for reinfusion. While the use of CTLs has proved effective in the 
cancer and posttransplant settings, CTL therapy for HIV infec-
tion appears to be safe but has, thus far, failed to durably control 
viremia in the absence of ART.8–10
One difference that may account for the previously observed 
lack of clinical efficacy of HIV-specific CTL is that those admin-
istered in HIV clinical trials thus far have largely been single-epi-
tope–specific T cell clones expanded in the presence of mitogens 
and administered without the benefit of ART in actively viremic 
patients.8–10 This contrasts with the polyclonal virus-specific CTLs 
expanded in the presence of multiple, whole antigens and growth 
cytokines that have been successful at targeting Epstein-Barr virus 
(EBV),3,4 cytomegalovirus, and adenovirus5–7 in immunocompro-
mised settings and EBV-positive lymphoma outside the hemato-
poietic stem cell transplantation setting. Hence, we proposed that 
developing an HIV-specific T cell product with broader antigen 
recognition would increase the ability of the T cells to target and 
clear HIV-infected cells, in the setting of an antilatency reagent to 
induce expression of quiescent viral genomes, and continued ART 
to prevent spread and viral epitope escape.
In this study, we have developed a novel strategy to expand 
cytotoxic T cells targeting multiple HIV antigens (HIV-specific T 
cells (HXTC)). We show that by using both autologous dendritic 
cells and phytohemagglutinin (PHA)-blasts as antigen-presenting 
cells (APCs), we can successfully expand HXTC lines from seven 
ART-established HIV patients who demonstrate robust cytotoxic 
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RESULTS
HXTCs expand to clinically relevant numbers and 
comprise mixed CD4+ and CD8+ T cells with an 
effector memory phenotype
To evaluate whether T cells could be expanded from the periph-
eral blood of HIV-infected patients on ART regardless of their 
human leukocyte antigen (HLA) type or medical history (Table 1), 
peripheral blood mononuclear cells (PBMCs) from seven patients 
were primed with autologous dendritic cell (DC) pulsed with Gag, 
Pol, and Nef PepMix in the presence of interleukin (IL)-7, IL-15, 
and IL-12 (Figure 1). PepMix is the commercialized term for pep-
tide libraries spanning regions of the antigens of interest: gag, pol, 
and nef. (JPT Peptide Technologies). The PepMixes consist of 150 
peptides that are 155 amino acids in length. These 15mers were 
selected based on a proprietary algorithm held by JPT that was 
used to determine which peptides provide the broadest cover-
age across all clades of HIV. After two more rounds of stimula-
tion (24–26 days) using autologous PepMix-pulsed PHA-blasts, 
ex vivo expanded HXTCs derived from seven patients showed a 
mean expansion of 145.6-fold (range: 37.2–287.0) starting from 1 
Table 1 Characteristics of patient samples used to generate HXTCs
ID Peak VL (copies/ml) Duration of suppressionb Protective HLA27
Specificity shown 
by IFN-γ ELIspot
Acute infectiona 231 84.5 × 106 6 years No Gag, Pol, Nef
250 0.75 × 106 6 years HLA-B27 Gag
ID CD4 Nadir (per ml) Duration of suppression Protective HLA
Specificity shown 
by IFN-γ ELIspot
423 16 9 years Unknown Nef
425 516 6 years No Gag, Pol, Nef
Chronic infection 492 232 3 years Unknown Gag, Pol, Nef
532 82 11 years Unknown Gag, Pol, Nef
546 195 13 years Unknown Gag, Pol, Nef
aAcute infection defined as within 45 days of infection and is determined by a negative or indeterminate HIV antibody test but positive viral load and p24 antigen 
test.28 bSuppression defined as undetectable viral load by standard commercial assays (below 50 copies/ml).
Figure 1 HXTC manufacturing process. Peripheral blood mononuclear cells (PBMCs) are isolated from 60–100 ml of whole blood samples from avi-
remic HIV+ patients. Monocytes are separated using plastic adherence and used to generate dendritic cells. Dendritic cells are pulsed with PepMixes 
spanning Gag, Pol, and Nef before being used to stimulate the nonadherent PBMC fraction which contains T cells. T cells undergo two more weekly 
stimulations by coculture with autologous, PepMix-pulsed PHA-blasts. During the third stimulation, irradiated K562 cells that have been geneti-
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million T cells on day 0 quantified using cell counting (Figure 2a). 
While the expansion was a wide range, even the lower end of this 
range provides robust enough expansion to achieve the numbers 
required for clinical use. Furthermore, previous clinical trials 
using adoptively transferred EBV-specific T cells showed efficacy 
despite a lower fold expansion observed during the manufactur-
ing process.3,11
These lines were predominantly CD3+CD8+ T cells (mean: 
84.2%; range: 65.97–97.14%). However, we did retain a propor-
tion of CD4+ T cells (mean: 16.9% (2.9–34.0%)). Despite the pres-
ence of CD4+ T cells, viral outgrowth was not observed in the cell 
cultures, and HXTC culture media was regularly supplemented 
with amprenavir (data not shown). After three stimulations (days 
24–26), T cell lines contained a subpopulation of CD3−CD56+ 
NK cells (mean: 8%; range: 0–23.9%). Moreover, we observed 
the majority of the expanded T cells had converted to an effec-
tor memory phenotype (CD3+CD45RA−CD62L−; mean: 74.0% 
(48.8–93.3%); n = 5; Figure 2b,c) which was encouraging due to 
studies showing the role of functional HIV-specific effector mem-
ory CD8 T cells in instances of ART-independent viral control.12,13
The overexpression of PD-1 is well characterized on the sur-
face of HIV-specific T cells from chronically infected patients 
and is considered a marker of T cell activation and immune dys-
function.14,15 We measured PD-1 expression on HXTCs that were 
expanded ex vivo for 21 days, 7 days after the third stimulation. 
As shown in Figure 2d,e, the percentage of PD-1+ cells in HXTCs 
Figure 2 CD8, effector memory HIV-specific T cells expand in response to Gag, Pol, and Nef stimulation. (a) 1 × 106 T cells were stimulated 
with Gag, Pol, and Nef PepMixes on day 0. Expansion is shown in absolute cell counts and was measured 10 days after the third stimulation. 
(b) Nonadherent PBMCS containing T cells (n = 3, error bars defined by SEM) and (c) HXTCs were phenotyped using extracellular flow cytometry 
for T cell markers (CD3, CD4, and CD8), NK cell markers (CD56+), and memory subsets (CD45RA and CD62L) 7–10 days after the third stimulation 
(n = 5, error bars defined as the SEM). (d) PD-1 expression on HXTCs or EBV-specific CTL generated from healthy, HIV-negative donors measured 
7–10 days after third stimulation (representative of n = 3). (e) Comparison of percentage of PD-1+ T cells found in HXTCs versus EBV-specific CTLs 
generated from healthy, HIV-negative donors (n = 3, error bars defined by SEM).
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was not different from that detected on EBV-specific CTL prod-
ucts that were expanded similarly from HIV-negative, healthy 
donors who have already shown efficacy in clinical trials.3,4
HXTC are specific for multiple HIV antigens
To confirm the multi HIV antigen-specific activity of the HXTCs, 
the cultures were evaluated for interferon (IFN)-γ secretion in 
response to individual PepMixes for each HIV antigen in ELIspot. 
Nonadherent PBMCs containing T cells from ART patients prior 
to expansion did not secrete IFN-γ in response to HIV antigens 
(Figure 3a). In contrast, HXTC lines secreted IFN-γ in response to 
HIV antigens Gag (median: 129.5 spot-forming cell (SFC)/1 × 105 
cells; range: 32–327.5), Pol (median: 97.5 SFC; range: 4–402.5, and 
Nef (median: 310.5 SFC; range: 0–863.5; Figure 3b) but did not 
respond to negative control actin or Oct4 PepMixes (median: 2.0 
SFC; range: 0–20) or media alone (median: 3.5 SFC; range: 0–60). 
To confirm that the observed responses were T cell mediated, we 
used MHC class I and class II blocking antibodies in the enzyme-
linked immunospot assay (ELIspot) assay. As shown in Figure 3c, 
the IFN-γ responses to Gag, Pol, and Nef were decreased in the 
presence of class I or class II antibodies, suggesting that there 
are HIV-specific CD8 and CD4 T cells. We further confirmed 
the presence of HIV-specific T cells within HXTC cultures by 
measuring intracellular IFN-γ. A mean of 6.36% of HXTCs were 
IFN-γ+ after a 12-hour exposure to HIV PepMixes (normalized to 
negative control, Figure 3d,e). Importantly, the HXTCs expanded 
from all seven HIV+ patients showed recognition of at least one 
HIV antigen. Furthermore, five HXTCs recognized all three HIV 
antigens, demonstrating the feasibility of generating a multianti-
gen-specific T cell product from a single culture (Figure 3f and 
Table 1).
HXTCs are polyfunctional and polyclonal
To determine the polyfunctionality and polyclonality of the 
ex vivo expanded HXTC, we evaluated their Vβ repertoire using 
flow cytometry and cytokine release in Elispot and ELISA assays. 
We found that HXTCs not only released IFN-γ but also tumor 
necrosis factor (TNF)-α and IL-2 upon exposure to Gag, Pol, and 
Nef (Figure 4a,b). Distinguishing this approach from strategies 
that utilize single-epitope–specific T cells, HXTCs were shown to 
be polyclonal by flow cytometry–based Vβ analysis (Figure 4c). 
HXTCs also recognized multiple epitopes within HIV antigens. 
Using IFN-γ ELIspot, we tested HXTCs against the Nef Group 
M consensus region broken up into multiple peptide pools con-
taining 7–8 peptides each and observed that HXTCs recognized 
multiple epitopes, suggesting that they are broadly epitope specific 
within each antigen (Figure 4d).
HXTCs can lyse antigen-pulsed and HIV-infected 
targets
To evaluate the cytolytic specificity of the HXTCs, we incubated 
the HXTCs with a panel of 51Chromium (51Cr)-labeled autolo-
gous target cells. HXTCs robustly lysed target cells pulsed with 
Gag (mean: 90.4 ± 6.68% lysis; n = 2), Pol (mean: 69.6 ± 1.22% 
lysis; n = 2), and Nef (mean: 44.4 ± 29.65% lysis; n = 3) at an effec-
tor to target ratio of 5:1. Importantly, HXTCs were specific since 
lysis of activated autologous target cells alone was not observed 
(1.9 ± 2.38% lysis; n = 4; Figure 5a,b, representative of n = 4). To 
further evaluate the antiviral activity of the HXTCs in vitro, we 
determined if they could inhibit HIV replication in autologous T 
cells. HXTCs or unexpanded autologous CD8+ T cells were cocul-
tured with autologous CD8-depleted PBMCs infected with a labo-
ratory strain of HIV JR-CSF, and p24 release was measured after 
7 days. At a HXTC to target ratio of 1:10, cocultures with HXTCs 
produced significantly less p24 than cocultures with unexpanded 
CD8 T cells (mean: 50.9; range: 9.5–86.4% p24 recovery versus 
unexpanded CD8: mean: 92.8; range: 42.0–135.0% p24 recovery; 
P = 0.035), indicative of inhibition of HIV replication in vitro 
(Figure 5c).
DISCUSSION
Although ART has increased the lifespan of HIV-infected patients, 
this treatment cannot fully eradicate the virus. The strict adher-
ence necessary for continuous suppression and associated costs, 
side effects resulting from long-term use, and the populations at 
high risk for drug resistance make finding alternative therapies 
that could provide a cure imperative. Due to our previous suc-
cesses treating immune-compromised patients with polyclonal 
T cells for other latent viruses (EBV and CMV),3–7 we sought to 
determine the feasibility of expanding polyclonal T cells to target 
HIV infection in acutely and chronically diagnosed HIV+ patients 
on suppressive ART and to characterize their function and deter-
mine their potential as an immunotherapy strategy.
In this study, we demonstrated that by the use of a novel expan-
sion protocol, we produced HXTCs that comprised CD8+ and 
CD4+ T cells had an effector memory phenotype, and the major-
ity of the T cell lines generated demonstrated reactivity to all three 
HIV antigens. This is in contrast to ex vivo unexpanded peripheral 
blood T cells, which failed to produce IFN-γ in response to stimu-
lation with Gag, Pol, and Nef.
One limitation of previous studies utilizing T cells targeting 
HIV is their specificity for a restricted number of epitopes within 
a single antigen.8–10 The majority of our HXTC lines recognized 
multiple epitopes within three HIV antigens, We achieved this 
using a single-culture methodology which is simple and cost 
effective for clinical scale production. To achieve sufficient expan-
sion of HXTCs for clinical use, we used genetically modified 
K562 cells (GM-K562), which have been engineered to express 
costimulatory molecules to drive T cell proliferation. Although 
the incorporation of these cells may pose a risk, tumor-specific 
T cells expanded using these cells are already being used clini-
cally.16 Prior to culturing GM-K562 cells with HXTCs, these cells 
are irradiated at 100 Gy which is enough to lose replicative abil-
ity. Also, our FDA-approved release criteria requires that the final 
product be less than 2% CD3negCD83pos cells and <0.1% CD3−, 
CD16/56−, CD32+, and CD83+ (GM-K562 cells) cells.
We intentionally selected Gag, Pol, and Nef antigens to target 
both early and late antigens17–19 so that the HXTCs would have 
the potential to target HIV+ cells at different stages of infection. 
Moreover, all three of these antigens have been correlated with 
viral control.20–22 Our data also suggests that HXTCs are CD8 
and CD4 restricted and recognize a broad number of epitopes. 
Since CD4 T cells are known to provide CD8 T cell help, aiding 
in memory, persistence, and effector functions.13,23 It is critical 
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that any T cell immunotherapy approach for HIV utilizes CD4 
T cells. While the infusion of a small percentage of CD4 T cells 
may seem counterintuitive, non-CD4–depleted T cells have been 
infused in the past, and no significant increase in viral load was 
observed.8 We envision administering HXTCs while maintaining 
the patient on ART therapy. Furthermore, it may be interesting 
to evaluate whether recent technologies that render CD4 T cells 
HIV resistant could be used in combination with our approach.24 
Figure 3 HXTCs have CD8 and CD4-mediated responses to multiple HIV antigens. (a) Nonadherent PBMCs on day 0 (n = 3, error bars defined by 
SEM) and (b) HXTCs (n = 7, error bars defined by the SEM) 10 days after the third stimulation were tested for IFN-γ release as a marker of T cell activa-
tion using IFN-γ ELIspot assay against media as a negative control, irrelevant antigens actin or Oct4 PepMixes as negative controls, HIV PepMixes, or 
staphylococcus enterotoxin B (SEB) as a positive control. (c) HXTCs were pretreated for 1 hour with no antibodies (black bar), MHC class I (solid gray 
bar), and class II (striped bar) blocking antibodies before being plated in an IFN-γ ELIspot assay against Gag, Pol, and Nef PepMixes (representative 
example of n = 3, error bars defined by the SD). (d,e) Intracellular IFN-γ staining in HXTCs after 12-hour exposure to HIV PepMixes, SEB (positive 
control), or no antigen (media, negative control) (n = 4, error bars defined by SD). (f) Summary of the number of antigens each HXTC line simultane-
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Additionally, we eliminated the need to deplete CD4+ T cells prior 
to the expansion process by incorporating the use of antiretroviral 
drugs during the manufacturing process. Amprenavir, a protease 
inhibitor, was used to grow HXTCs, as well as the PHA-blasts used 
as APCs. This did not impact the ability to yield functional T cells 
against HIV antigens, and no viral outgrowth was observed.
HXTCs demonstrated strong antiviral effector functions 
in vitro. When exposed to Gag, Pol, and Nef antigens, HXTCs 
produced large amounts of IFN-γ, TNF-α, and IL-2 cytokines 
important for the antiviral response. Previous studies also showed 
the importance of polyfunctional cytokine production in T cell-
mediated control of HIV.25 HXTCs were also able to specifically 
lyse target cells presenting Gag, Pol, and Nef epitopes, even at low 
effector to target ratios, and they showed greater suppression of 
HIV replication in infected T cell cocultures compared to unex-
panded CD8 T cells.
Figure 4 HXTCs release multiple proinflammatory cytokines and are polyclonal. (a) IL-2 and (b) TNF-a release by HXTCs in response to no anti-
gen (neg), Gag, Pol, and Nef PepMix was measured by ELISA as described in the Materials and Methods section (representative of n = 3, error bars 
represent SD). (c) Vβ usage of HXTCs was analyzed using a flow cytometry–based assay, IOTest Beta Mark TCR V Kit (BD Biosciences). (d) HXTCs were 
tested against the Nef group M consensus region broken up into peptide pools containing seven to eight peptides each in an IFN-γ ELIspot assay. 
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Although we generated seven HXTC lines, we did not prese-
lect which patient to derive these lines from based on HLA type or 
disease prognosis. These patients varied in their time to ART ini-
tiation, and some had reached severe T cell deficiency and AIDS 
in the past. Despite this, we were able to expand HXTCs from all 
seven HIV+ patients on suppressive ART irrespective of the clini-
cal history, thus highlighting the feasibility and broad applicability 
of our approach in the clinical setting.
In summary, functionally active multi-HIV antigen-specific 
T cells can easily be manufactured using the same protocol for any 
patient, and we envision that any ART-established HIV patient 
would be eligible for future clinical studies. Furthermore, this 
T cell therapy platform is also complementary to other eradica-
tion strategies such as the use of histone deacetylase inhibitors 
that can induce viral reactivation and unmask the latent reservoir 
so that persistent infection may be cleared by immune effectors, 
such as HXTCs.
MATERIALS AND METHODS
Patient samples. Peripheral blood was obtained from seven aviremic 
HIV patients on ART at the University of North Carolina–Chapel Hill 
(Chapel Hill, NC). All patients had provided written informed con-
sent, and samples were obtained through a blood collection protocol 
approved by the University of North Carolina–Chapel Hill Institutional 
Review Board in accordance with the Declaration of Helsinki. Use of 
coded peripheral blood samples was approved by the Baylor College of 
Medicine and Children's National Medical Center Institutional Review 
Boards. Approximately, 60–100 ml of blood was drawn, and PBMCs were 
isolated by density gradient centrifugation and cryopreserved.
Generation of APCs. For DC generation, fresh or cryopreserved PBMCs 
were plated on 6-well plates and incubated for 2 hours in DC media 
(CellGenix DC media; CellGenix, Freiberg, Germany) supplemented 
with 2 mmol/l GlutaMax (Invitrogen, Carlsbad, CA). Nonadherent 
cells were harvested and cryopreserved. Adherent cells were cultured in 
dendritic cell media in the presence of IL-4 (1,000 U/ml) and granulo-
cyte macrophage colony-stimulating factor (800 U/ml; both from R&D 
Systems, Minneapolis, MN). On day 5, immature DCs were matured 
using a cytokine cocktail consisting of IL-4 (1,000 U/ml), granulocyte 
macrophage colony-stimulating factor (800 U/ml), IL-6 (10 ng/ml), 
 TNF-α (10 ng/ml), IL-1β (10 ng/ml; all from R&D Systems), and PGE2 
(1 μg/ml; Sigma-Aldrich, St Louis, MO)26 and were harvested after 24–48 
hours of maturation for use as APCs.
To generate PHA-blasts, PBMCs were stimulated with the mitogen 
PHA-P (5 μg/ml; Sigma-Aldrich) in the presence of IL-2 to promote 
blast formation. PHA-blasts were cultured in RPMI-1640 supplemented 
with 10% human serum (Valley Medical, Winchester, VA), 2 mmol/l 
GlutaMax, and IL-2 (100 U/ml; R&D Systems). To prevent possible viral 
outgrowth, PHA-blast cultures were treated with 0.5 ng/ml of amprenavir 
every other day (GlaxoSmithKline, Philadelphia, PA).
Generation of HXTCs. We define the use of “T cell line” in this manu-
script as a single-culture of ex vivo expanded T cells derived from an indi-
vidual donor. These cells are not immortalized. To generate HXTC lines, 
matured DCs were harvested and pulsed with Gag, Pol, and Nef peptide 
libraries (0.2 μg/ml; Ultra PepMix; JPT Peptide Technologies, Berlin, 
Germany) and used as APCs at a stimulator-to-responder ratio of 1:10 
with nonadherent PBMCs, which contain T cells. T cells were cultured 
in RPMI-1640 supplemented with 40% Clicks media (Irvine Scientific, 
Santa Ana, CA), 10% human AB serum, and 2 mmol/l GlutaMax. For 
the first HIV stimulation, a cytokine mix containing IL-7 (10 ng/ml), 
Figure 5 HXTCs are cytotoxic and inhibit viral outgrowth in infected cultures. (a,b) Ability of HXTCs to lyse antigen-expressing targets was 
measured using an 8-hour 51Chromium-release assay. Target cells consisted of autologous PHA-blasts that were pulsed with either media or Gag, Pol, 
or Nef PepMixes and were loaded with chromium. HXTCs were cultured with target cells pulsed with only the antigens they were specific for, which 
was predetermined by IFN-γ ELIspot assay. (c) Autologous CD8 depleted PBMCs were infected with HIV strain, JR-CSF by spinoculation. HXTCs or 
unexpanded CD8 T cells were cocultured with the infected target cells for 7 days before p24 release was measured using ELISA. *P ≤ 0.05. All error 
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IL-12 (10 ng/ml), IL-15 (5 ng/ml; all from R&D Systems) was added. 
Nine days later, T cells were restimulated with peptide-pulsed autolo-
gous irradiated (30 Gy) PHA-blasts at a stimulator-to-responder ratio of 
1:4 on days 10 to 12 and maintained in IL-15 (5 ng/ml)–supplemented 
media on the second stimulation or IL-2 (50 U/ml)–supplemented 
media for the third stimulation cycle. On the third stimulation, irradi-
ated (100 Gy) K562 cells that have been genetically modified to express 
costimulatory molecules, CD80, CD83, CD86, and 41-BBL (K562-cs) 
were added to the T cell:PHA-blast coculture to provide further costim-
ulation (K562-cs cells were a gift from Dr Cliona Rooney at Baylor 
College of Medicine and described in ref. 16). HXTCs were expanded in 
presence of amprenavir (0.5 ng/ml) which was added to the cultures on 
the day of each stimulation and on days 3 and 5 poststimulation.
Phenotyping of HXTCs. HXTCs or EBV-specific CTLs from healthy 
donors (generated as described in refs. 3,4) were phenotyped with extra-
cellular antibody staining with anti-CD3, CD4, CD8, CD45RA and 
CD45RO, CCR7, CD62L, CD56, CD16, and PD-1 or IOTest Beta Mark 
TCR V Kit (all from BD Biosciences, Franklin Lakes, NJ) and analyzed on 
a BD FACSCalibur, FACSCanto, or Accuri Flow Cytometer. Control sam-
ples labeled with appropriate isotype-matched antibodies were included 
in each experiment. Data were analyzed using FCS Express software (De 
Novo Software, Los Angeles, CA).
IFN-γ ELIspot assay. The antigen specificity of the HXTCs was tested in 
an IFN-γ ELIspot assay using peptide pools as antigen. Recognition of the 
pooled HIV antigens was compared with no-peptide (media) control and 
irrelevant peptide pools not used for T cell generation (Oct4 or actin; JPT 
Peptide Technologies). Staphylococcus enterotoxin B (SEB; Sigma) was 
used as a positive control. Nonadherent PBMCS were tested on day 0 prior 
to expansion, and HXTCs were tested 10 days after the third stimulation.
Millipore Multi Screen HTS filter plates (Millipore, Billerica, MA) 
were coated with IFN-γ capture antibody (Mabtech, Cincinnati, OH) 
at a concentration of 10 μg/ml overnight at 4 °C. Plates were washed 
with phosphate-buffered saline and blocked for 1 hour at 37 °C to rule 
out nonspecific protein binding. Nonadherent PBMCs were plated at 
2 × 105/well, and HXTCs were plated at 1 × 105/well. Cells were washed 
and resuspended and stimulated with PepMix or single peptides at a 
concentration of 0.1 mg/ml. The plates were incubated for 16–20 hours at 37 
°C. For development, plates were washed six times with phosphate-buffered 
saline /0.05% Tween 20 and incubated with biotinylated IFN-γ detection 
antibody (0.5 μg/ml; Mabtech) for 2 hours at 37 °C, followed by incubation 
with streptavidin-coupled alkaline phosphatase complex (Vectastain; Vector 
Laboratories, Burlingame, CA) for 1 hour at room temperature. Spots were 
developed by incubation with 3-amino-9-ethylcarbazole substrate solution. 
SFC were counted and evaluated by Zellnet Consulting (Fort Lee, NJ) using 
an automated plate reader system (Carl Zeiss, Thornwood, NY). A T cell 
line positive for a given antigen is defined as having greater than double the 
SFC obtained in the negative control but at least 50 SFC/1e5 cells (or 2e5 
cells in the case of nonadherent PBMCS).
HLA-blocking experiments. The HLA-restriction of antigen recognition 
was tested in IFN-γ–ELIspot using blocking antibodies against HLA class I 
and II (both from BD Biosciences, San Jose, CA). HXTCs were incubated 
with HLA class I or II blocking antibodies for 1 hour prior to being plated 
with media (negative control), Gag, Pol, or Nef PepMix, and SEB (positive 
control). ELIspot plates were incubated and developed as described earlier.
Intracellular cytokine staining for IFN-γ. 1 × 106 HXTCs were stimulated 
with media alone (negative control), Gag or Nef PepMixes, or SEB (posi-
tive control). After 3–4 hours, brefeldin A (BD Biosciences, San Jose, CA) 
was added to block Golgi transport. After 8 hours, cells were washed, per-
meabilized, and stained with extracellular (CD3-FITC; BD Biosciences) 
and intracellular antibodies (IFNy-APC; BD Biosciences). Samples were 
analyzed on a BD Accuri Flow Cytometer. Control samples labeled with 
appropriate isotype-matched antibodies were included in each experi-
ment. Data were analyzed using FCS Express software.
ELISA for cytokine release. Detection of cytokines release in the superna-
tants of HXTC cocultures were analyzed by an ELISA specific for TNF-α 
(Invitrogen) or IL-2 (BD Biosciences), following the manufacturers’ pro-
tocols. Seven to 10 days after the third stimulation, 1 × 105 HXTCs were 
stimulated in duplicates with Gag, Pol, and Nef PepMix, media, or SEB as 
a positive control. Twelve hours later, supernatant was collected for ELISA 
analysis.
51Cr-release cytotoxicity assay. The cytolytic activity of HXTCs was 
assessed in 51Cr-release assays 10 days after the third stimulation. Unpulsed 
autologous PHA-blasts (negative control) or HIV PepMix-pulsed PHA-
blasts were labeled with 51Cr sodium chromate for 1 hour at 37 °C, washed, 
and resuspended with HXTCs at effector-to-target ratios from 40:1 to 5:1 
and incubated for 6–8 hours. Spontaneous lysis was determined by mea-
suring 51Cr-release into the supernatant on a gamma-counter from each 
target cell in the absence of effectors. Maximum lysis was measured by 
addition of 1% Triton X-100 (Sigma-Aldrich) to target cells. Specific lysis 
was calculated as follows: specific lysis (%) = (experimental release − spon-
taneous release)/(maximum release − spontaneous release) × 100.
Viral inhibition assay. CD8 depleted, PBMCs were cultured in complete 
media containing IL-2 (50 U/ml) and PHA (2 µg/ml) for 2 days before 
being superinfected with HIV laboratory strain JR-CSF via spinocula-
tion. The infected target cells were cocultured for 7 days with autologous 
HXTCs or unexpanded autologous CD8 T cells (that were isolated using 
magnetic beads (Stem Sep; Stem Cell Technologies, Vancouver, British 
Columbia, Canada) added at varying effector-to-target ratios. Seven days 
later, supernatant was assayed for HIV-1 gag p24 concentration by ELISA 
(ABL, Rockville, MD); results are shown as %p24 production normalized 
to a positive infection control with no effector cells added.
Statistical analysis. Data are summarized as mean ± SD or mean (range), 
unless noted otherwise in the text or figure legends. Student’s t-test was 
used to determine whether there was a statistically significant difference 
between samples, with two-tailed P values less than 0.05 indicating a sig-
nificant difference. Two-way ANOVA with Holm-Sidak correction was 
used to determine statistical significance of IFN-γ release in response to 
HIV antigens compared to the negative control.
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